Clinical Trial

Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)

Name: Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a) — clinical trial record (NCT07551505)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this Phase 1 clinical study is to evaluate the safety and tolerability of a single dose of BSA204 injection in Chinese adults with borderline high levels of lipoprotein(a) \[Lp(a)\].

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-04-19.

Trial Details

NCT Number	NCT07551505
Lead Sponsor	Bisirna Therapeutics (Suzhou) Co., Ltd.
Conditions	Dyslipidemias
Enrollment	40 participants
Start Date	2026-04-20
Primary Completion	2027-07-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-28